- Home
- APM vs QLGN Comparison
APM vs QLGN Comparison
Compare APM & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APM
- QLGN
- Stock Information
- Founded
- APM 2010
- QLGN 1996
- Country
- APM United Kingdom
- QLGN United States
- Employees
- APM N/A
- QLGN N/A
- Industry
- APM Biotechnology: Pharmaceutical Preparations
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- APM Health Care
- QLGN Health Care
- Exchange
- APM Nasdaq
- QLGN Nasdaq
- Market Cap
- APM 4.0M
- QLGN 3.4M
- IPO Year
- APM 2018
- QLGN N/A
- Fundamental
- Price
- APM $0.74
- QLGN $4.18
- Analyst Decision
- APM
- QLGN
- Analyst Count
- APM 0
- QLGN 0
- Target Price
- APM N/A
- QLGN N/A
- AVG Volume (30 Days)
- APM 69.7K
- QLGN 54.9K
- Earning Date
- APM 12-27-2024
- QLGN 11-14-2024
- Dividend Yield
- APM N/A
- QLGN N/A
- EPS Growth
- APM N/A
- QLGN N/A
- EPS
- APM N/A
- QLGN N/A
- Revenue
- APM $431,378.00
- QLGN N/A
- Revenue This Year
- APM $157,729.10
- QLGN N/A
- Revenue Next Year
- APM N/A
- QLGN N/A
- P/E Ratio
- APM N/A
- QLGN N/A
- Revenue Growth
- APM N/A
- QLGN N/A
- 52 Week Low
- APM $0.46
- QLGN $3.34
- 52 Week High
- APM $17.49
- QLGN $30.50
- Technical
- Relative Strength Index (RSI)
- APM 41.12
- QLGN 43.01
- Support Level
- APM $0.73
- QLGN $3.53
- Resistance Level
- APM $0.78
- QLGN $4.39
- Average True Range (ATR)
- APM 0.09
- QLGN 0.33
- MACD
- APM 0.04
- QLGN 0.06
- Stochastic Oscillator
- APM 64.47
- QLGN 50.98
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.